Get the Stockscreener App
1.80
2.70%
-0.05
After Hours:
1.62
-0.18
-10.00%
Alto Neuroscience Inc stock is traded at $1.80, with a volume of 481.84K.
It is down -2.70% in the last 24 hours and down -42.12% over the past month.
Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals' neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.
See More
Previous Close:
$1.85
Open:
$1.805
24h Volume:
481.84K
Relative Volume:
1.65
Market Cap:
$48.73M
Revenue:
-
Net Income/Loss:
$-49.81M
P/E Ratio:
-0.8349
EPS:
-2.156
Net Cash Flow:
$-42.93M
1W Performance:
-20.70%
1M Performance:
-42.12%
6M Performance:
-82.78%
1Y Performance:
-87.22%
1-Day Range:
$1.60
$1.8203
1-Week Range:
$1.60
$2.25
52-Week Range:
$1.60
$17.55
Alto Neuroscience Inc Stock (ANRO) Company Profile
Name
Alto Neuroscience Inc
Sector
Industry
Phone
773-255-5012
Address
650 CASTRO STREET, SUITE 450, MOUNTAIN VIEW
Compare ANRO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANRO
Alto Neuroscience Inc
|
1.80 | 48.73M | 0 | -49.81M | -42.93M | -2.156 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Alto Neuroscience Inc Stock (ANRO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-23-24 | Downgrade | Rodman & Renshaw | Buy → Neutral |
| Oct-23-24 | Downgrade | Wedbush | Outperform → Neutral |
| Sep-03-24 | Initiated | Wedbush | Outperform |
| Feb-27-24 | Initiated | Jefferies | Buy |
| Feb-27-24 | Initiated | Robert W. Baird | Outperform |
| Feb-27-24 | Initiated | Stifel | Buy |
| Feb-27-24 | Initiated | TD Cowen | Outperform |
| Feb-27-24 | Initiated | William Blair | Outperform |
View All
Alto Neuroscience Inc Stock (ANRO) Latest News
Charles Schwab Investment Management Inc. Sells 32,137 Shares of Alto Neuroscience, Inc. (NYSE:ANRO) - Defense World
Alto Neuroscience, Inc. (NYSE:ANRO) Shares Acquired by Bank of New York Mellon Corp - Defense World
ANRO stock touches 52-week low at $2.33 amid market challenges - Investing.com Australia
What is William Blair’s Forecast for ANRO Q1 Earnings? - Defense World
What is Wedbush’s Estimate for ANRO FY2029 Earnings? - Defense World
Brokerages Set Alto Neuroscience, Inc. (NYSE:ANRO) PT at $16.75 - Defense World
William Blair Reiterates “Outperform” Rating for Alto Neuroscience (NYSE:ANRO) - Defense World
Alto Neuroscience says its funded through 2028 - Green Market Report
ALTO NEUROSCIENCE Earnings Results: $ANRO Reports Quarterly Earnings - Nasdaq
Alto Neuroscience Inc. (ANRO) reports earnings - Quartz
Alto Neuroscience Reports Full-Year 2024 Financial Results And Recent Business Highlights - Marketscreener.com
Alto Neuroscience, Inc. SEC 10-K Report - TradingView
Alto Neuroscience Reports Full-Year 2024 Financial Results and Recent Business Highlights - Business Wire
Alto Neuroscience (ANRO) Expected to Announce Quarterly Earnings on Thursday - Defense World
ANRO stock touches 52-week low at $3.23 amid market challenges - MSN
Alto Neuroscience, Inc. (NYSE:ANRO) Shares Bought by Rhumbline Advisers - Defense World
Schizophrenia Drugs Market: Top Competitors, Market Share, - openPR
Alto Neuroscience (NYSE:ANRO) Trading Up 8.8% – Should You Buy? - Defense World
Alto Neuroscience Is Down Nearly 35% This Year, But Retail Traders Keep Flocking To Micro-Cap Stock - Asianet Newsable
1 ‘Strong Buy’ Penny Stock With 270% Upside to Load Up On in March - MSN
1 ‘Strong Buy’ Penny Stock With 270% Upside To Load Up On In March - Barchart
Jefferies Predicts Up to ~500% Jump for These 2 ‘Strong Buy’ Stocks - Yahoo Finance
Alto Neuroscience advances trial for depression treatment - MSN
ANRO stock touches 52-week low at $2.97 amid market challenges - Investing.com Canada
Alto Neuroscience to Participate in Upcoming Investor Conferences - Business Wire
Alto Neuroscience Announces U.S. Patent Granted Covering Alto-300 As A Treatment For Patients With Major Depressive Disorder Characterized By An Electroencephalogram Biomarker - Marketscreener.com
Revolutionary Depression Treatment Patent: How Alto's EEG Biomarker Could Transform Patient Care - StockTitan
Alto Neuroscience Announces U.S. Patent Granted Covering ALTO-300 as a Treatment for Patients with Major Depressive Disorder Characterized by an Electroencephalogram Biomarker - Business Wire
Alto Neuroscience reports positive outcomes from Phase IIb trial of MDD therapy - MSN
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Alto Neuroscience, Inc. (ANRO) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Stifel maintains Buy on Alto Neuroscience stock, $10 target - MSN
Alto Neuroscience advances trial for depression treatment By Investing.com - Investing.com Australia
Stifel maintains Buy on Alto Neuroscience stock, $10 target By Investing.com - Investing.com Nigeria
Alto Neuroscience : Corporate Presentation -February 12, 2025 at 08:29 am EST - Marketscreener.com
Alto Neuroscience announces interim analysis from ALTO-300 trial - TipRanks
Alto Neuroscience Says Favorable Outcome In Interim Analysis Of ALTO-300 Phase 2B Major Depressive Disorder Trial - Marketscreener.com
Alto Neuroscience Announces Favorable Outcome from Interim Analysis of ALTO-300 Phase 2b Major Depressive Disorder Trial - The Bakersfield Californian
The Schall Law Firm Invites Investors With Losses In Alto Neuroscience, Inc. To Join A Securities Fraud Investigation - Louisiana First News
Schizophrenia Drugs Market reached US$ 10.03 billion in 2024 - openPR
Alto Neuroscience, Inc. (NYSE:ANRO) Receives $20.00 Average Price Target from Analysts - MarketBeat
Alto Neuroscience announces $75 million ATM offering - MSN
Alto Neuroscience Files For Mixed Shelf Of Up To $300 Million -February 03, 2025 at 05:06 pm EST - Marketscreener.com
Alto Neuroscience announces $75 million ATM offering By Investing.com - Investing.com UK
Alto Neuroscience, Inc. (NYSE:ANRO) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Precision neuropsychiatry spotlight: a BioCentury podcast - BioCentury
JPMorgan Chase & Co. Acquires 20,536 Shares of Alto Neuroscience, Inc. (NYSE:ANRO) - Defense World
Alto Neuroscience Inc Stock (ANRO) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):